Gene Sequencing Tech Provider 10x Genomics' Q3 Sales Fall Short On Expectations, But CEO Sees Opportunity Ahead
Gene Sequencing Tech Provider 10x Genomics' Q3 Sales Fall Short On Expectations, But CEO Sees Opportunity Ahead
"Third-quarter revenue fell short of our expectations," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "The previously announced modifications we made to our commercial processes and organization to increase effectiveness represented a significant change in how we engage with customers. The transition was more disruptive than we anticipated, especially in the Americas. At the same time, our customers continue to be cautious with their spending, particularly around capital purchases, which notably impacted instrument sales during the quarter. 10x Genomics Inc (NASDAQ:TXG) stock is trading lower after the company, on Wednesday, released preliminary financial results for the third quarter of 2024, revealing a mixed performance.
纳斯达克股票TXG的10x genomics股票在公司周三发布2024年第三季度初步财务业绩后下跌，显示出不佳的表现。
The company's revenue for the quarter totaled approximately $151.7 million versus the consensus of $162.245 million, marking a slight 1% decline compared to the same period in 2023.
本季度公司的营业收入约为15170万美元，低于16224.5万美元的共识，较2023年同期略有下降1%。
Also Read: What's Going On With 10x Genomics Stock On Wednesday?
也可阅读：纳斯达克10x genomics股票周三发生了什么？
"Third-quarter revenue fell short of our expectations," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "The previously announced modifications we made to our commercial processes and organization to increase effectiveness represented a significant change in how we engage with customers. The transition was more disruptive than we anticipated, especially in the Americas. At the same time, our customers continue to be cautious with their spending, particularly around capital purchases, which notably impacted instrument sales during the quarter.
“第三季度营业收入未达到我们的预期，”10x genomics的联合创始人兼首席执行官Serge Saxonov表示。“我们此前宣布的改进商业流程和组织以提高效率所做的修改代表了与客户互动方式的重大变化。转变比我们预期的更具破坏性，尤其在美洲地区。与此同时，我们的客户在支出方面继续保持谨慎，尤其是在资本支出方面，这在本季度显著影响了仪器销售。”
10x Genomics' instruments sales fell significantly, with a 46% drop to $19.1 million. This included $7.6 million from Chromium instruments and $11.4 million from Spatial instruments.
10x genomics的仪器销售大幅下滑，下降了46%，至1910万美元。其中来自Chromium仪器的760万美元和来自Spatial仪器的1140万美元。
Consumables sales grew by 10%, reaching $126.2 million. Of this, Chromium consumables accounted for $96.5 million, and Spatial consumables generated $29.7 million.
耗材销售增长了10%，达到12620万美元。其中，Chromium耗材占9650万美元，而Spatial耗材产生了2970万美元。
Additionally, services revenue experienced a robust 48% growth, contributing $6.4 million.
此外，服务收入增长了强劲的48%，贡献了640万美元。
Revenue trends varied geographically. The company saw an 11% decline in the Americas, bringing revenue to $87.8 million.
收入趋势在地域上有所不同。该公司在美洲地区看到了11%的下降，带来的营业收入为8780万美元。
However, strong growth was reported in both EMEA and APAC regions, with 18% and 15% increases, respectively. EMEA revenue totaled $37.9 million, while APAC generated $26.0 million.
然而，欧洲、中东、非洲和亚太地区的增长均表现强劲，分别增长18%和15%。 欧洲、中东、非洲的营业收入总额为$3790万，而亚太的营业收入为$2600万。
The company also reported cash and cash equivalents of approximately $398 million as of September 30, 2024.
截至2024年9月30日，公司报告的现金及现金等价物约为$39800万。
The company plans to provide full guidance for the year during its earnings call on October 29, 2024.
公司计划于2024年10月29日的业绩会上提供全年的全面指导。
During its second quarter 2024 earnings release, the gene sequencing company cut its fiscal year 2024 sales guidance to $640 million to $660 million from a prior range of $670 million to $690 million versus the consensus of $648.21 million.
在2024年第二季度业绩发布期间，这家基因测序公司将其2024财年销售指导从先前范围的$67000万至$69000万下调至$64000万至$66000万，而市场预期为$64821万。
Price Action: TXG stock is down 26.20% at $15.35 during the premarket session at the last check on Thursday.
股价走势：TXG股价在周四最后一次预交易中报跌26.20%，报价$15.35。
- Baxter's North Carolina Facility Manufactures ~60% Of IV Fluids And Peritoneal Dialysis Solutions, Senator Demands Immediate Action To Protect Patient Care Amid Shortage.
- 百特斯北卡罗来纳工厂生产约60%的静脉注射液和腹膜透析液，参议员要求立即采取行动保护患者护理，避免短缺。
